by Cort Johnson | Oct 5, 2016 | Homepage, Low Dose Naltrexone, Treatment
Drug companies interested in ME/CFS? A race to produce the first drug for ME/CFS? A race? Those almost sound like fantasies but that’s the message Jarred Younger brought in his recent video talk. The bottom line, he said, is that over the last three months he’s...
by Cort Johnson | Oct 3, 2016 | Antivirals, Fibromyalgia, Flexeril, Lyrica, Treatment
Tomnya had everything going for it; a novel approach to pain and good Phase II trial results, but Tonix’s reformulation of Flexeril that was expected to help with both sleep and pain tanked in its critical Phase III trial. Check out what happened with it, and...
by Cort Johnson | Sep 24, 2016 | Diagnosis, Fibromyalgia, Genetics, Homepage, Treatment
The Proove genetic test for fibromyalgia – is the first genetic test that I know of for FM. It’s not a diagnostic test – it’s focused on guiding treatment options. It identifies ten genes that can affect drug metabolism and one gene that affects...
by Cort Johnson | Sep 23, 2016 | Advocacy, CBT-GET
The issue at stake was a big one. It asked whether changes to the original protocol of the PACE trial ended up stacking the deck. It was easy to see how they might have; some of the recovery criteria were so weird as to seem ridiculous. The changes in the studies...
by Cort Johnson | Sep 21, 2016 | Fibromyalgia, Fibromyalgia and Pain, Treatment
Chronic pain costs more than heart disease, cancer and diabetes combined yet gets a fraction of their funding. Judy Foreman knows well the cost of our medical systems dysfunctional approach to pain. A medical journalist used to good medical care, she was dismayed by...
by Cort Johnson | Aug 26, 2016 | Ampligen, Treatment
Ampligen became the first drug ever approved for use in ME/CFS when ANMAT, Argentine’s FDA, approved the drug for use in severe ME/CFS patients. The approval should provide a clear pathway for Ampligen’s approval elsewhere. The U.S. is the odd man out in...